Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
17.59
+0.42 (2.45%)
At close: Oct 9, 2026, 4:00 PM EDT
17.55
-0.04 (-0.23%)
After-hours: Oct 9, 2026, 7:58 PM EDT
Summit Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Summit Therapeutics stock has a consensus rating of "Buy" and an average price target of $29.7. The average 1-year stock price forecast is 68.85% higher than the current stock price, while the lowest is $11.88 (-32.46%) and the highest is $42.96 (+144.23%).
Price Target: $29.7 (+68.85%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 10 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 5 | 5 | 7 | 6 | 6 |
| Sell | 2 | 2 | 2 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold Maintains $18 → $20 | Hold | Maintains | $18 → $20 | +13.70% | Oct 1, 2026 |
| Jefferies | Jefferies | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 29, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 29, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 29, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $34 | Buy | Maintains | $34 | +93.29% | Sep 29, 2026 |
Financial Forecast
Revenue This Year
3.89M
Revenue Next Year
55.46M
from 3.89M
Increased by 1,326.97%
EPS This Year
-1.12
from -1.41
EPS Next Year
-1.14
from -1.12
EPS and Forward PE are based on non-GAAP adjusted numbers.